Several studies have reported a prominent role for GM-CSF and to a lesser extent IL-3 in autoimmune diseases, and for some of them such as multiple sclerosis (MS) [68] and rheumatoid arthritis (RA) [69,70], humanized blocking antibodies are now being evaluated in clinical trials. Here, CSF2 is linked to multiple sclerosis.